Skin and soft tissue antibiotics: Difference between revisions
No edit summary |
|||
| Line 25: | Line 25: | ||
==[[Yersinia]]== | ==[[Yersinia]]== | ||
{{Yersinia antibiotics}} | {{Yersinia antibiotics}} | ||
==See Also== | ==See Also== | ||
Revision as of 23:29, 29 April 2015
Skin and Soft Tissue
Erysipelas
Coverage for S. pyogenes
- Penicillin G 300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg (first line therapy[1]) OR
- Clindamycin 450mg (5mg/kg) PO q8hrs x 10 days (if PCN allergic) OR
- Cephalexin 500mg (6.25mg/kg) PO q6hrs x 10 days OR
- Ceftriaxone 1g (50mg/kg) IV once daily x 10 days OR
- Levofloxacin 500mg PO/IV daily x 10 days OR
- Amoxicillin/Clavulanate 500mg PO BID x 10 days (generally reserved for failure of first line therapy)
Bullous Erysipela or MRSA suspected: trimethoprim-sulfamethoxazole, clindamycin, doxycycline, or minocycline
Pediatric
- Penicillin G <30kg: 300,000 U/day IM; >30kg: 600,000-1 million U/day IM OR
- Cephalexin 25-50mg/kg/day PO divided q6-8h x 10 days (max 500mg/dose) OR
- Clindamycin 30mg/kg/day PO divided TID x 10 days (max 1.8g/day) OR
- Ceftriaxone 50mg/kg IV daily (max 2g) x 10 days
Cellulitis/Superficial Abscess with Cellulitis
Tailor antibiotics by regional antibiogram
Outpatient
- 5 day treatment duration
- Cephalexin 500mg PO q6hrs OR
- Add DS 1 tab PO BID if MRSA suspected
- Clindamycin 450mg PO TID covers Strep and Staph
- Cephalexin 500mg PO q6hrs OR
Pediatric Outpatient
- Cephalexin 25-50mg/kg/day PO divided q6-8h (max 500mg/dose) OR
- Add 8-12mg/kg/day (TMP) PO divided BID if MRSA suspected
- Clindamycin 30-40mg/kg/day PO divided TID (max 1.8g/day)
Inpatient
- Vancomycin 20mg/kg IV q12hrs OR
- Clindamycin 600mg IV q8hrs OR
- Linezolid 600mg IV q12hrs OR
- Daptomycin 4mg/kg IV once daily
Pediatric Inpatient
- Vancomycin 15mg/kg IV q6hrs OR
- Clindamycin 10-13mg/kg IV q8hrs (max 900mg/dose) OR
- Linezolid <12yr: 10mg/kg IV q8hrs; >12yr: 600mg IV q12hrs
- Doxycycline 100mg PO/IV q12hrs daily + Cefepime 1g IV q12hrs x 10 days
- Ciprofloxacin 400mg IV q12hrs x 10 days
- Ciprofloxacin 500mg PO q12hrs x 10 days
- TMP/SMX 2 DS tablets PO q12hrs x 10 days
- Ceftriaxone 1g (50mg/kg) IV q24hrs
Impetigo
Coverage for MSSA, MRSA, Group A Strep
Topical therapy
- Mupirocin 2% ointment q8hrs x 5 days
Oral Therapy
- Cephalexin 500mg (6.25mg/kg) PO q6hrs x 10 days OR
- Amoxicillin/Clavulanate 875mg (12.5mg/kg) PO q12hrs x 10 days OR
- Clindamycin 450mg PO q8hrs (or 10mg/kg PO q6hrs) x 10 days OR
- Dicloxacillin 500mg (3mg/kg) PO q6hrs x 10 days
Pediatric
- Mupirocin 2% ointment applied TID x 5 days
- Cephalexin 25-50mg/kg/day PO divided q6-8h x 7-10 days (max 500mg/dose) OR
- Amoxicillin/Clavulanate 25mg/kg/day PO divided BID x 7-10 days OR
- Clindamycin 30mg/kg/day PO divided TID (max 1.8g/day) OR
- Dicloxacillin 12.5-25mg/kg/day PO divided q6h x 7-10 days
Bioterrorism
Anthrax
Postexposure Prophylaxis
Patient should be vaccinated at day #0, #14, #28
- Ciprofloxacin 500mg PO q12hrs x 60 days OR
- Doxycycline 100mg PO q12hrs x 60 days
Cutaneous Anthrax (not systemically ill)
- Ciprofloxacin 500mg PO q12hrs x 60 days
- Doxycycline 100mg PO q12hrs x 60 days
Inhalation or Cutaneous with systemic illness
- Ciprofloxacin 400mg IV q12hrs x 60 days OR
- Doxycycline 100mg IV q12hrs x 60 days PLUS
- Clindamycin 900mg IV q8hrs
Pediatric Postexposure Prophylaxis
- Ciprofloxacin 15mg/kg PO q12hrs x 60 days
- Doxycycline 2.2mg/kg PO q12hrs x 60 days
Pediatric Cutaneous Anthrax (not ill)
- Same as pediatric postexposure dosing and duration
Pediatric Inhalational or Cutaneous (systemically ill)
- Ciprofloxacin 15mg/kg IV q12hrs OR
- Doxycycline 2.2mg/kg IV q12hrs PLUS
- Clindamycin 7.5mg/kg q6hrs
- Imipenem/Cilastatin 1g IV q6h for at least 2wk
- Imipenem/Cilastatin Neonates >32 wk gestation; 40-75 mg/kg/day IV divided q8-12h for at least 2wk; 1 month and older; 100 mg/kg/day IV divided q6h for at least 2wk
- Rifampin 600 mg IV q12h for at least 2 wk as part of a multi-drug regimen; Switch to PO abx x60 days total if inhalational exposure
- Rifampin Neonates >32 wk gestation; 10-20 mg/kg/day IV divided q12-24h for at least 2 wk as part of multi-drug regimen; 1+ mo; 20 mg/kg/day IV divided q12h for at least 2 wk as part of multi-drug regimen; Max: 300 mg/dose
- Imipenem/Cilastatin 1g IV q6h for at least 2wk
- Imipenem/Cilastatin Neonates >32 wk gestation; 40-75 mg/kg/day IV divided q8-12h for at least 2wk; 1 month and older; 100 mg/kg/day IV divided q6h for at least 2wk
- Rifampin 600 mg IV q12h for at least 2 wk as part of a multi-drug regimen; Switch to PO abx x60 days total if inhalational exposure
- Rifampin Neonates >32 wk gestation; 10-20 mg/kg/day IV divided q12-24h for at least 2 wk as part of multi-drug regimen; 1+ mo; 20 mg/kg/day IV divided q12h for at least 2 wk as part of multi-drug regimen; Max: 300 mg/dose
Botulism
Supportive Care
- Early ventilatory support
- Consider intubation when vital capacity <30% predicted or <12cc/kg
- Wound Managment
- Early wound debreedment with surgical consult.
- Also exclude Necrotizing fasciitis and coverage with same broad antibiotic coverage
Foodborne Botulism
- Equine Serum Botulism Antitoxin
- only for patients > 1yo
- Antitoxin obtained through CDC or local Department of Health.
Infant Botulism (<1yo)
- Human-based Botulism IG 100mg/kg IV x 1 dose (BabyBIG)
- infusion divided into 25mg/kg/hr IV x 15 min followed by 50mg/kg/hr if no allergic reactions
- Stop infusion after total of 100mg/kg infused
- BabyBIG obtained through CDC or local Department of Health
Inhalational Botulism
- Equine Serum Botulism Antitoxin
- only for patients > 1yo
- Antitoxin obtained through CDC or local Department of Health
Wound Botulism
- Individualize therapy with ID consultant
- Broad antibiotic coverage same as for Necrotizing fasciitis while awaiting wound cultures
Smallpox
- IMMEDIATE NOTIFICATION OF PUBLIC HEALTH AUTHORITIES
- Vaccine administered up to 3 days post-exposure was effective in preventing infection as well as lessening the severity of the disease if infection occurred [2]
Post-Exposure Prophylaxis
- Vaccinia Vaccine (administer within 72hrs of exposure)
Active Disease
- Supportive care and wound care for open lesions
- Vaccinia Vaccine within the first 72hrs can decrease total disease severity and within 7 days may decrease symptoms
- Vaccination is not efficacious once the patient has developed rash[3]
Tularemia
Postexposure Prophylaxis
- Doxycycline 100mg PO q12hrs x 14 days OR
- Ciprofloxacin 500mg PO q12hrs x 10 days
Active Disease
- Streptomycin 1g (15mg/kg) IM q12hrs daily x 10 days (First line) OR
- Gentamicin 5mg/kg/day IV/IM once daily x 10 days OR
- Ciprofloxacin 400mg (15mg/kg) IV q12hrs x 10 days OR
- Doxycycline 100mg (2.2mg/kg) IV q12hrs x 14 days OR
- Chloramphenicol 15mg/kg IV q6hrs x 14 days
- Streptomycin 1g IM q12h x10 days; Maximum dose: 2 g/day (adjust dose based on serum levels)
- Streptomycin 15mg/kg IM q12h x10 days; Maximum dose: 2 g/day (adjust dose based on serum levels)
Pediatric
- Gentamicin 2.5mg/kg IV/IM q8hrs x 10 days
- Doxycycline 2.2mg/kg PO/IV q12hrs x 14 days (max 100mg/dose)
- Ciprofloxacin 15mg/kg PO/IV q12hrs x 10 days (max 500mg PO / 400mg IV)
Yersinia
Postexposure Prophylaxis
- Doxycycline 100mg (2.2mg/kg) PO q12hrs OR
- Ciprofloxacin 500mg (20mg/kg) PO q12hrs OR
- Chloramphenicol 25mg/kg PO q6hrs
- only if age > 2
Active Disease
- Gentamicin 5mg/kg IV/IM once daily x 10 days OR
- Ciprofloxacin 500mg (20mg/kg) PO q12hrs x 10 days OR
- Doxycycline 200mg (2.2mg/kg) PO/IV daily
- Streptomycin 1g IM q12h x10 days; Maximum dose: 2 g/day (adjust dose based on serum levels)
- Streptomycin 15mg/kg IM q12h x10 days; Maximum dose: 2 g/day (adjust dose based on serum levels)
Pediatric
- Gentamicin 2.5mg/kg IV/IM q8hrs x 10 days
- Doxycycline 2.2mg/kg PO/IV q12hrs (max 100mg/dose)
- Ciprofloxacin 15mg/kg PO q12hrs (max 500mg/dose)
- Chloramphenicol 25mg/kg PO/IV q6hrs (max 4g/day); age >2 only
See Also
Antibiotics by diagnosis
- Bone and joint antibiotics
- Cardiovascular antibiotics
- ENT antibiotics
- Eye antibiotics
- GI antibiotics
- GU antibiotics
- Neuro antibiotics
- OB/GYN antibiotics
- Pulmonary antibiotics
- Skin and soft tissue antibiotics
- Bioterrorism antibiotics
- Environmental exposure antibiotics
- Immunocompromised antibiotics
- Post exposure prophylaxis antibiotics
- Pediatric antibiotics
- Sepsis antibiotics
- Arthropod and parasitic antibiotics
For antibiotics by organism see Microbiology (Main)
References
- ↑ Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.
- ↑ Kman NE, Nelson RN. Infectious agents of bioterrorism: a review for emergency physicians. Emerg Med Clin North Am. 2008 May;26(2):517-47
- ↑ Cdc.gov. 2020. Prevention and Treatment | Smallpox | CDC. [online] Available at: <https://www.cdc.gov/smallpox/prevention-treatment/index.html> [Accessed 11 September 2021].
